Qiagen to acquire Nextal Biotechnology
Qiagen has agreed to buy Canada's Nextal Biotechnology for up to $14.2 million, with $9.7 million in cash and the rest paid out according to predetermined milestones. Nextal has developed products that "simplify the process of sample preparation of proteins for subsequent crystallographic analysis."
- read this press release for more
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
